1515-27-1

Basic information

• Product Name: 1-METHYLPIPERIDIN-4-ONE OXIME
• Synonyms: ART-CHEM-BB B015961;AKOS B015961;4-HYDROXYIMINO-N-METHYLPIPERIDINE;1-METHYLPIPERIDIN-4-ONE OXIME;1-METHYLPIPERIDIN-4-ONE OXIME HYDROCHLORIDE;1-Methyl-4-piperidinone oxime;NSC 363971;N-(1-methylpiperidin-4-ylidene)hydroxylamine
• CAS NO: 1515-27-1
• Molecular Formula: C₆H₁₂N₂O
• Molecular Weight: 128.17
• Mol File: 1515-27-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 128.5-129℃
• Boiling Point: 220.9°Cat760mmHg
• Flash Point: 87.4°C
• Appearance: /
• Density: 1.14g/cm³
• Vapor Pressure: 0.0412mmHg at 25°C
• PKA: 12.21±0.20(Predicted)
• CAS DataBase Reference: 1-METHYLPIPERIDIN-4-ONE OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYLPIPERIDIN-4-ONE OXIME(1515-27-1)
• EPA Substance Registry System: 1-METHYLPIPERIDIN-4-ONE OXIME(1515-27-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 1515-27-1(Hazardous Substances Data)

Usage

General Description

1-Methylpiperidin-4-one oxime is a chemical compound that is commonly used as a reagent in organic synthesis and as a chelating agent in chemical analysis. It is an organic oxime derivative, which is a class of compounds that contain the functional group C=NOH. 1-Methylpiperidin-4-one oxime is often used as a stabilizer for aldehydes and ketones, as it can form stable complexes with these carbonyl compounds and prevent their further reactions. It can also be used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. Additionally, it is a versatile chelating agent in metal complexation and can be used in analytical chemistry for the determination of metal ions in solution.

InChI:InChI=1/C6H12N2O/c1-8-4-2-6(7-9)3-5-8/h9H,2-5H2,1H3/p+1

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 13221-89-1 1-methyl-4-oxo-piperidine-3-carboxylic acid methyl ester 

Downstream Products

• 30417-87-9 1-methylpiperidin-4-one O-(4-nitrophenyl)oxime 
• 1387002-70-1 1-methylpiperidin-4-one-O-4-(phenylsulfonyl)phenyl oxime 
• 1242065-24-2 1-methyl-4-nitroso-4-piperidinyl 4-chlorobenzoate 
• 5441-40-7 1-methyl-1,4-diazepan-5-one 
• 41838-46-4 4-Amino-1-methylpiperidine 

Relevant articles and documents

Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists

A number of O-alkynyloximes of tropinone and N-methyl-4-piperidinone have been synthesized and evaluated for muscarinic activity. The affinities of these oximes were tested in homogenates of cerebral cortex, heart, and submandibulary glands from rats using [3H]pirenzepine and [3H]-N- methylscopolamine as radioligands. The oximes bind to the cortical muscarinic receptors with pK(i) values varying from 3 to 7. Higher binding affinities were observed for the O-alkynyl tropinone oximes than the corresponding piperidinone analogues. Binding to the muscarinic sites in the heart and submandibulary glands was also observed but with lower affinities. Good M1 subtype selectivity (10-fold or greater) was observed with some oximes (26a, 28a, 32a) at the cortical sites. These oximes also attenuated scopolamine- induced impairment of the water mask task in mice. Functional assays for M3 activity on the rat aorta showed that all oximes possessed M3 agonist action but M2 agonist activity was not observed at the endothelium-denuded rabbit aorta. Analysis of the quantitative structure-activity relationship (QSAR) indicated that the Connolly surface area is an important determinant of activity, accounting for 70% of the variation in cortical binding affinity among the oximes.

PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY

Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF

The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.